Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
After finishing at $0.32 in the prior trading day, Elevation Oncology Inc (NASDAQ: ELEV) closed at $0.31, down -3.23%. In other words, the price has decreased by -$3.23 from its previous closing price. On the day, 1.0 million shares were traded.
Ratios:
Our goal is to gain a better understanding of ELEV by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 19.40 and its Current Ratio is at 19.40. In the meantime, Its Debt-to-Equity ratio is 0.67 whereas as Long-Term Debt/Eq ratio is at 0.67.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Stephens on March 24, 2025, Downgraded its rating to Equal-Weight and sets its target price to $1 from $5 previously.
On March 21, 2025, Piper Sandler Downgraded its rating to Neutral which previously was Overweight but kept the price unchanged to $0.70.
Leerink Partners Downgraded its Outperform to Market Perform on March 21, 2025, while the target price for the stock was maintained at $1.
Stock Price History:
Over the past 52 weeks, ELEV has reached a high of $4.33, while it has fallen to a 52-week low of $0.22. The 50-Day Moving Average of the stock is -5.82%, while the 200-Day Moving Average is calculated to be -44.35%.
Shares Statistics:
A total of 59.22M shares are outstanding, with a floating share count of 53.00M. Insiders hold about 10.50% of the company’s shares, while institutions hold 47.25% stake in the company.
Earnings Estimates
The firm’s stock currently is rated by 3.0 analysts. The consensus estimate for the next quarter is -$0.1, with high estimates of -$0.09 and low estimates of -$0.13.
Analysts are recommending an EPS of between -$0.56 and -$0.77 for the fiscal current year, implying an average EPS of -$0.65. EPS for the following year is -$0.41, with 4.0 analysts recommending between -$0.31 and -$0.54.
